Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees

Affiliations

¹ Indian Council of Medical Research-National Institute of Virology, Pune, India.
² Bharat Biotech International Limited, Genome Valley, Hyderabad, India.
³ Indian Council of Medical Research, V. Ramalingaswami Bhawan, New Delhi, India.

Pragya D Yadav et al. Clin Infect Dis. 2022.

. 2022 Jan 29;74(2):366-368.

doi: 10.1093/cid/ciab411.

¹ Indian Council of Medical Research-National Institute of Virology, Pune, India.
² Bharat Biotech International Limited, Genome Valley, Hyderabad, India.
³ Indian Council of Medical Research, V. Ramalingaswami Bhawan, New Delhi, India.

No abstract available

Comment in

Neutralization Potential of Covishield Vaccinated Individuals Sera Against B.1.617.1.
Yadav PD, Sapkal GN, Abraham P, Deshpande G, Nyayanit DA, Patil DY, Gupta N, Sahay RR, Shete AM, Kumar S, Panda S, Bhargava B. Yadav PD, et al. Clin Infect Dis. 2022 Feb 11;74(3):558-559. doi: 10.1093/cid/ciab483. Clin Infect Dis. 2022. PMID: 34036309 No abstract available.
Reduced severity of SARS-CoV-2 infection by Kappa variant of interest (B.1.617.1) in a healthcare worker post-vaccination from Gujarat, India.
Sahay RR, Shete AM, Sapkal GN, Deshpande GR, Shah AD, Kumar S, Abraham P, Yadav PD. Sahay RR, et al. Indian J Med Res. 2022 May-Jun;155(5&6):575-577. doi: 10.4103/ijmr.ijmr_1390_21. Indian J Med Res. 2022. PMID: 35975349 Free PMC article. No abstract available.